A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

NCT05482971 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythemia

Interventions

DRUG: Ropeginterferon alfa-2b-njft (P1101)

Sponsor

PharmaEssentia